Browsing: Psychedelic

Federal award will help answer how psychedelic treatment works and who is most likely to benefit

Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health conditions. The news comes on the heels of positive clinical trial results of several different psychedelics,…

Eli Lilly will buy AtaiBeckley for up to US$3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions

The Departments of Veterans Affairs and Health and Human Services signed an agreement Monday to increase coordination on research into psychedelic drugs for treating veterans’ mental health disorders

The U.S. government’s Department of Health and Human Services (HHS) recently announced partnering with the Department of Veterans Affairs (VA) to fast-track the development of psychedelic-assisted therapies to treat veterans living with mental health issues like post-traumatic stress disorder (PTSD), depression, traumatic brain injury (TBI), and more. After years of interest, 2026 has marked a…